Clinical Trial Update: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating abiraterone acetate with or without cabazitaxel and prednisone in metastatic castration-resistant prostate cancer previously tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Cabazitaxel (cabazitaxel)
• PREDNISONE (Prednisone)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-08